{"title":"A Review of Dextromethorphan-Quinidine for the Treatment of Agitation in Dementia.","authors":"Amber N Khan, Kayla S Murphy, Rajesh R Tampi","doi":"10.4088/PCC.24nr03737","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To provide an updated summary of the literature on dextromethorphan quinidine for the treatment of agitation in dementia.</p><p><p><b>Data Sources:</b> PubMed, Medline, APA PsycINFO, Embase, and Cochrane Collaboration were searched from inception to January 7, 2024 using the keywords <i>dementia</i>, <i>dextromethorphan</i>, and <i>quinidine</i>. The search was limited to the English language and human subjects.</p><p><p><b>Study Selection:</b> Twenty-four articles underwent full-text review. One randomized controlled trial (RCT) and 2 case reports were included. Twenty one studies were excluded because they were editorials or commentaries, were not treatment studies, or were assessing outcomes other than agitation.</p><p><p><b>Data Extraction:</b> The 3 included studies underwent full-text review. A qualitative analysis of the data was performed, and abstracted data included patient diagnosis and symptoms, treatment dose and duration of dextromethorphan-quinidine, and symptom response.</p><p><p><b>Data Synthesis:</b> One RCT and 2 case reports showed an improvement in dementia-related agitation with dextromethorphan-quinidine treatment; however, the data are limited.</p><p><p><b>Conclusion:</b> Though all the identified studies demonstrated that treatment with dextromethorphan improved agitation, more evidence is needed to establish its potential efficacy and associated risks for this patient population. Future studies should include diverse types of dementia, a variety of treatment settings, and longer duration of treatment.</p><p><p><i>Prim Care Companion CNS Disord 2024;26(6):24nr03737</i>.</p><p><p>\n <i>Author affiliations are listed at the end of this article.</i>\n </p>","PeriodicalId":22814,"journal":{"name":"The primary care companion for CNS disorders","volume":"26 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The primary care companion for CNS disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4088/PCC.24nr03737","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To provide an updated summary of the literature on dextromethorphan quinidine for the treatment of agitation in dementia.
Data Sources: PubMed, Medline, APA PsycINFO, Embase, and Cochrane Collaboration were searched from inception to January 7, 2024 using the keywords dementia, dextromethorphan, and quinidine. The search was limited to the English language and human subjects.
Study Selection: Twenty-four articles underwent full-text review. One randomized controlled trial (RCT) and 2 case reports were included. Twenty one studies were excluded because they were editorials or commentaries, were not treatment studies, or were assessing outcomes other than agitation.
Data Extraction: The 3 included studies underwent full-text review. A qualitative analysis of the data was performed, and abstracted data included patient diagnosis and symptoms, treatment dose and duration of dextromethorphan-quinidine, and symptom response.
Data Synthesis: One RCT and 2 case reports showed an improvement in dementia-related agitation with dextromethorphan-quinidine treatment; however, the data are limited.
Conclusion: Though all the identified studies demonstrated that treatment with dextromethorphan improved agitation, more evidence is needed to establish its potential efficacy and associated risks for this patient population. Future studies should include diverse types of dementia, a variety of treatment settings, and longer duration of treatment.
Prim Care Companion CNS Disord 2024;26(6):24nr03737.
Author affiliations are listed at the end of this article.
期刊介绍：
Founded in 1998, The Primary Care Companion for CNS Disorders (ISSN 2155-7780), formerly The Primary Care Companion to The Journal of Clinical Psychiatry, is an international, peer-reviewed, online-only journal, and its articles are indexed by the National Library of Medicine. PCC seeks to advance the clinical expertise of primary care physicians and other health care professionals who treat patients with mental and neurologic illnesses. PCC publishes research from disciplines such as medicine, nursing, pharmacy, and psychology, especially as it pertains to integrated delivery systems and interdisciplinary collaboration. PCC focuses on providing information of direct clinical utility and giving a voice to clinician researchers. Practice-based research from individuals and groups with clinical expertise is particularly welcome. Pertinent manuscript types include: -Original research -Systematic reviews -Meta-analyses -Case reports and series -Commenting letters to the editor Articles published in PCC typically cover attention-deficit/hyperactivity disorder, depression, bipolar disorder, anxiety, addiction, sleep disorders, pain, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
